Slide 1: Cover letter to stock exchanges on investor presentation
November 14, 2024 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol: KOPRAN Dear S
Slide 2: Corporate Presentation Q2 FY 2024-25
CORPORATE PRESENTATION Q2 FY 2024-25
Slide 3: Disclaimer
This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not
Slide 4: Performance
PERFORMANCE • Financial Highlights • Operational Performance • API • Formulation
Slide 5: Financial Highlights
Q-2 Q-1 Q-2 HY HY PARTICULARS 2024-25 2024-25 2023-24 2024-25 2023-24 Revenue from 15,156 13,944 15,259 29,100 26,959 Operations Other Income 100 263 13 362 252 EBITDA* 1,474 1,816 2,283 3,290 2,914 Finance Costs 223 218 194 442 377 Depreciation 385 387 277 773 603 Tax Expenses 226 364 448 590 532 N
Slide 6: Operational Performance
OPERATIONAL ~ PERF ORMA NCE Kopran
Slide 7: APIs Operational Highlights: Segment-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX Q2 FY 2024-25 (Rs. In Lakhs) HY 2024-25 (Rs. In Lakhs) 45 50 -290 629 723 68 Anti- Diabetic Anti- Diabetic 1180 684 1097 2477 Anti- Infective Anti- Infective 35 12 641 Antibiotic-Urological 12 Antibiotic-Urological Anti-Hypertensive Anti-Hypertens
Slide 8: APIs Operational Highlights: Market-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX Q2 FY 2024-25 (Rs. In Lakhs) HY 2024-25 (Rs. In Lakhs) 2930 7490 Export Sales Export Sales Local Sales Local Sales 4785 9215 Total Rs. 7,715 Lakhs Total Rs. 16,705 Lakhs
Slide 9: Formulations Operational Highlights: Region-wise Sales Break-up
Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP Q2 FY 2024-25 (Rs. In Lakhs) HY 2024-25 (Rs. In Lakhs) 1260 Africa 1479 Africa 1454 3040 CANADA 1138 CANADA 472 Latem Latem 407 60 Middle East and North Africa Middle East and North Africa 328 616 South Africa South Africa 540 Southeast
Slide 10: Formulations Operational Highlights: Product-wise Revenue Mix
Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX Q2 FY 2024-25 (Rs. In Lakhs) HY 2024-25 (Rs. In Lakhs) 5588 2993 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 4233 6521 Total Rs. 7,226 Lakhs Total Rs. 12,109 Lakhs
Slide 11: Company Overview
Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth
Slide 12: A Global Pharmaceutical Company
A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International 50+ Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations and app
Slide 13: API Vertical
API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENT Anti-hypertensive Development, manufacturing and Atenolol sale of diverse APIs and Advanced Macrolide Intermediates Cephalosporins - Non-Sterile & Sterile Neuromodulator Urological One of the leaders in Atenolol
Slide 14: Formulations Product Segments
FORMULATIONS PRODUCT SEGMENTS FORMULATIONS VERTICAL Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs PENICILLIN-BASED NON-PENICILLIN FINISHED ORAL BASED FINISHED Catering 100% export markets of both Regulated and
Slide 15: Strategic Imperatives
STRATEGIC IMPERATIVES GROWTH AND SUSTAINABILITY COST LEADERSHIP Focus on R&D to develop niche, Development of intermediates for APIs high-value/high-volume APIs and intermediates Reducing dependence on China to move towards self sufficiency Capacity expansion Optimising operational cost
Slide 16: Regulatory Compliance
REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards FORMULATIONS ACCREDITATIONS of manufacturing and quality at its all plants API ACCREDITATIONS Approved by 15 countries including MHRA (UK), SAPHRA South The plant
Slide 17: Financial Performance
FINANCIA L PERF ORMA NCE ~ Kopwan
Slide 18: Snapshot: Sales, EBITDA, Finance Costs, Net Profit
SNAPSHOT SALES/OTHER INCOME (₹ LAKHS) EBITDA * (₹ LAKHS) 8,739 8,178 62,920 7,441 55,405 50,980 48,813 5,180 36,013 4,696 29,462 3,290 2019-20 2020-21 2021-22 2022-23 2023-24 Sep-24 2019-20 2020-21 2021-22 2022-23 2023-24 Sep-24 891 859 6,161 6,103 5,096 624 608 512 442 2,723 2,120 1,848 2019-20 202
Slide 19: Building Shareholder Value Year on Year
BUILDING SHAREHOLDER VALUE YEAR ON YEAR EBITDA ( ₹ Lakhs) RoE ( % ) RoCE ( % ) 28.3 8,739 25.3 8,178 7,441 22.4 20.1 5,180 14.5 4,996 11.4 11.8 11 9.7 3,290 8.3 7.5 6.3 2019-20 2020-21 2021-22 2022-23 2023-24 Sep-24 2019-20 2020-21 2021-22 2022-23 2023-24 Sep-24 - Return on Networth/Equity - Return
Slide 20: Financial Summary (Rs. Lakhs)
(Rs. Lakhs) PARTICULARS Sep-2024 FY 2023-24 FY 2022-23 FY 2021-22 FY 2020-21 FY 2019-20 Equity Share Capital 4,821 4,821 4,821 4,821 4,325 4,325 Other Equity 44,910 44,303 39,104 37,796 20,178 14,643 Networth 49,731 49,125 43,925 42,617 24,503 18,968 Fixed Assets(net) 29,106 27,830 23,457 18,623 15,
Slide 21: Board of Directors
BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. ADARSH RAJENDRA SOMANI MRS. MAMTA BIYANI MR. NARAYAN ATAL EXECUTIVE VICE CHAIRMAN DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR DR. SIDDHAN SUBRAMANIAN DR. SUNITA BANERJI MR. SUSHEEL SOMANI MR. VARUN SURENDRA SOMANI INDEPENDENT DIRECTOR INDEPENDENT DIR
Slide 22: About Kopran Limited
ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New P